HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ivan D Horak Selected Research

futuximab

7/2018Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
4/2018Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
6/2015Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
10/2013Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ivan D Horak Research Topics

Disease

39Neoplasms (Cancer)
01/2022 - 01/2004
8Colorectal Neoplasms (Colorectal Cancer)
01/2020 - 09/2005
5Non-Hodgkin Lymphoma (Lymphosarcoma)
10/2009 - 04/2004
3Breast Neoplasms (Breast Cancer)
03/2015 - 03/2004
3Hypoxia (Hypoxemia)
09/2011 - 11/2008
3Carcinoma (Carcinomatosis)
06/2011 - 04/2005
3Neoplasm Metastasis (Metastasis)
11/2008 - 04/2005
3Lymphoma (Lymphomas)
12/2005 - 12/2003
3Colonic Neoplasms (Colon Cancer)
11/2005 - 04/2005
2Neuroblastoma
01/2022 - 10/2010
2Glioma (Gliomas)
01/2022 - 09/2011
2Residual Neoplasm
01/2020 - 04/2005
2Glioblastoma (Glioblastoma Multiforme)
07/2018 - 11/2008
2Stomach Neoplasms (Stomach Cancer)
01/2018 - 01/2018
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2016 - 10/2013
2B-Cell Lymphoma (Lymphoma, B Cell)
08/2005 - 12/2003
2Multiple Myeloma
07/2005 - 12/2004
1Hodgkin Disease (Hodgkin's Disease)
01/2022
1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
01/2022
1Head and Neck Neoplasms (Head and Neck Cancer)
01/2021
1Triple Negative Breast Neoplasms
01/2020
1Squamous Cell Carcinoma of Head and Neck
01/2016
1Prostatic Neoplasms (Prostate Cancer)
12/2011
1Necrosis
10/2010

Drug/Important Bio-Agent (IBA)

9AntibodiesIBA
01/2022 - 04/2005
9ErbB Receptors (EGF Receptor)IBA
01/2020 - 06/2011
9Proteins (Proteins, Gene)FDA Link
01/2020 - 01/2004
9Monoclonal AntibodiesIBA
04/2018 - 03/2004
7Pharmaceutical PreparationsIBA
01/2018 - 12/2003
5LigandsIBA
01/2020 - 12/2011
5Irinotecan (Camptosar)FDA LinkGeneric
09/2011 - 04/2005
5Carcinoembryonic AntigenIBA
11/2005 - 04/2005
4Cetuximab (Erbitux)FDA Link
01/2021 - 10/2013
4futuximabIBA
07/2018 - 10/2013
4Messenger RNA (mRNA)IBA
11/2017 - 11/2008
4EZN-2208IBA
09/2011 - 03/2008
4Immunoglobulin G (IgG)IBA
12/2005 - 04/2005
3Immunoconjugates (Immunoconjugate)IBA
01/2022 - 07/2005
3LuciferasesIBA
12/2011 - 10/2010
3HaptensIBA
11/2005 - 10/2005
3Radioisotopes (Radionuclides)IBA
10/2005 - 04/2005
3Rituximab (Mabthera)FDA Link
08/2005 - 04/2004
3AntigensIBA
04/2005 - 04/2004
2RNA (Ribonucleic Acid)IBA
01/2020 - 11/2008
2EpitopesIBA
12/2017 - 10/2013
2Trastuzumab (Herceptin)FDA Link
11/2017 - 03/2015
2Neutralizing AntibodiesIBA
11/2017 - 04/2013
2Tyrosine Kinase InhibitorsIBA
04/2013 - 06/2011
2Phosphotransferases (Kinase)IBA
04/2013 - 06/2011
2Lapatinib (GW572016)FDA Link
04/2013 - 06/2011
2Transcription Factors (Transcription Factor)IBA
12/2011 - 11/2008
2Antisense OligonucleotidesIBA
12/2011 - 02/2010
2Topoisomerase I InhibitorsIBA
09/2011 - 10/2010
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2011 - 10/2010
2Doxorubicin (Adriamycin)FDA LinkGeneric
10/2010 - 07/2005
2ProdrugsIBA
10/2010 - 04/2008
2Immunotoxins (Immunotoxin)IBA
12/2005 - 05/2005
2Peptides (Polypeptides)IBA
11/2005 - 11/2005
2epratuzumabIBA
08/2005 - 04/2004
2Complement System Proteins (Complement)IBA
04/2005 - 04/2004
2IodineIBA
04/2005 - 03/2004
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2022
1Chimeric Antigen ReceptorsIBA
01/2022
1Insulin-Like PeptidesIBA
01/2021
1BuffersIBA
01/2020
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
01/2020
1human ERBB2 proteinIBA
01/2020
1Immune Checkpoint InhibitorsIBA
01/2019
1epidermal growth factor receptor VIIIIBA
07/2018
1Circulating Tumor DNAIBA
04/2018
1emibetuzumabIBA
01/2018
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2018
1Neuregulin-1 (Neuregulin 1)IBA
11/2017
1Panitumumab (Vectibix)FDA Link
06/2015
1pertuzumabIBA
03/2015
1Caspase 3 (Caspase-3)IBA
10/2013
1Gefitinib (Iressa)FDA Link
04/2013
15'-ACCaagtttcttcAGC-3'IBA
12/2011
1enzalutamideIBA
12/2011
1AndrogensIBA
12/2011
1Androgen Receptors (Androgen Receptor)IBA
12/2011
1abirateroneIBA
12/2011
1Testosterone (Sustanon)FDA Link
12/2011
1matrigelIBA
09/2011
1Matrix Metalloproteinases (MMPs)IBA
10/2010
1Histones (Histone)IBA
10/2010
1Therapeutic UsesIBA
10/2010
1Vincristine (Oncovin)FDA LinkGeneric
10/2010
1Cisplatin (Platino)FDA LinkGeneric
10/2010
1DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA
10/2010
1Topotecan (Hycamtin)FDA LinkGeneric
10/2010
1FenretinideIBA
10/2010
1SurvivinIBA
02/2010
1EZN 3042IBA
02/2010

Therapy/Procedure

20Therapeutics
01/2022 - 03/2004
5Radioimmunotherapy
11/2005 - 03/2004
3Aftercare (After-Treatment)
01/2020 - 09/2011
2Immunotherapy
01/2022 - 01/2019
2Drug Therapy (Chemotherapy)
08/2005 - 04/2005
1Castration
12/2011